RecruitingNot ApplicableNCT07712107

A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model: A Multi-center Prospective Randomized Controlled Trial


Sponsor

Xijing Hospital

Enrollment

10,000 participants

Start Date

Jun 15, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a multicenter, randomized controlled trial. The plan is to enroll eligible participants and randomly assign them to two groups: one group will undergo testing using a combined model of "multi-target blood methylation + fecal FIT + fecal calpetin"; those with positive results will immediately undergo standard gastrointestinal endoscopy, while those with negative results will enter routine observation; the other group will undergo only routine observation and follow-up. All enrolled participants will undergo a 5-year prospective follow-up, during which information on gastrointestinal cancer incidence and mortality will be collected through regular contact and review of medical records. The primary endpoint of the study is the difference in 5-year all-gastrointestinal cancer mortality between the two groups.This project aims to use a randomized controlled trial design to evaluate whether an active screening strategy based on a combined model can effectively reduce the population-level mortality from gastrointestinal cancers compared to routine surveillance. The objective is to provide high-level evidence for establishing a new screening strategy that reduces the disease burden and delivers public health benefits. It lays the foundation for validating novel biomarkers and exploring the biological and behavioral factors that influence screening outcomes, and offers clear decision-making support for optimizing China's comprehensive prevention and control system for gastrointestinal cancers.


Eligibility

Min Age: 45 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Multi-target blood methylation + fecal FIT + fecal calprotectin for people with gastrointestinal tumors. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 45 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMulti-target blood methylation + fecal FIT + fecal calprotectin

The intervention group underwent testing using a combined model of "multi-target blood methylation + fecal FIT + fecal calprotectin"; those with positive results subsequently underwent standard gastrointestinal endoscopy, while those with negative results were placed under routine observation.


Locations(6)

Gaoyao District People's Hospital, Zhaoqing City, Guangdong Province

Zhaoqing, Guangdong, China

The 960th Hospital of the Joint Support Force of the People's Liberation Army of China

Jinan, China

Yanting County Tumor Hospital

Mianyang, China

Wuwei Cancer Hospital of Gansu Province

Wuwei, China

Wuxi People's Hospital

Wuxi, China

Zhaoqing First People's Hospital, Guangdong Province

Zhaoqing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07712107


Related Trials